A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Issue 8 (20th August 2014)

• Record Type: Journal Article
• Authors: King, Lindsay Y; Canasto-Chibuque, Claudia; Johnson, Kara B; Yip, Shun; Chen, Xintong; Kojima, Kensuke; Deshmukh, Manjeet; Venkatesh, Anu; Tan, Poh Seng; Sun, Xiaochen; Villanueva, Augusto; Sangiovanni, Angelo; Nair, Venugopalan; Mahajan, Milind; Kobayashi, Masahiro; Kumada, Hiromitsu; Iavarone, Massimo; Colombo, Massimo; Fiel, Maria Isabel; Friedman, Scott L; Llovet, Josep M; Chung, Raymond T; Hoshida, Yujin
• Is Part Of: Gut. Volume 64:Issue 8(2015)
• Page Start: 1296
• Page End: 1302
• Publication Date: 2014-08-20
• Subjects: HEPATITIS C -- CIRRHOSIS -- GENE EXPRESSION; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2014-307862
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: The number of patients with HCV-related cirrhosis is increasing, leading to a rising risk of complications and death. Prognostic stratification in patients with early-stage cirrhosis is still challenging. We aimed to develop and validate a clinically useful prognostic index based on genomic and clinical variables to identify patients at high risk of disease progression. Design: We developed a prognostic index, comprised of a 186-gene signature validated in our previous genome-wide profiling study, bilirubin (>1 mg/dL) and platelet count (<100 000/mm 3 ), in an Italian HCV cirrhosis cohort (training cohort, n=216, median follow-up 10 years). The gene signature test was implemented using a digital transcript counting (nCounter) assay specifically developed for clinical use and the prognostic index was evaluated using archived specimens from an independent cohort of HCV-related cirrhosis in the USA (validation cohort, n=145, median follow-up 8 years). Results: In the training cohort, the prognostic index was associated with hepatic decompensation (HR=2.71, p=0.003), overall death (HR=6.00, p<0.001), hepatocellular carcinoma (HR=3.31, p=0.001) and progression of Child–Turcotte–Pugh class (HR=6.70, p<0.001). The patients in the validation cohort were stratified into high-risk (16%), intermediate-risk (42%) or low-risk (42%) groups by the prognostic index. The high-risk group had a significantly increased risk of hepatic decompensation (HR=7.36, p<0.001), overall death (HR=3.57, p=0.002), liver-related death (HR=6.49, p<0.001) and all liver-related adverse events (HR=4.98, p<0.001). Conclusions: A genomic and clinical prognostic index readily available for clinical use was successfully validated, warranting further clinical evaluation for prognostic prediction and clinical trial stratification and enrichment for preventive interventions.